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Taponen S, Jantunen A, Pyörälä E, Pyörälä S: Efﬁcacy of targeted 5-day combined
parenteral and intramammary treatment of clinical mastitis caused by penicillin-
susceptible or penicillin-resistant Staphylococcus aureus. Acta vet. scand. 2003, 44,
53-62. – Combined parenteral and intramammary treatment of mastitis caused by
Staphylococcus aureus was compared to parenteral treatment only. Cows with clinical
mastitis (166 mastitic quarters) caused by S. aureus treated by veterinarians of the Am-
bulatory Clinic of the Faculty of Veterinary Medicine during routine farm calls were in-
cluded. Treatment was based on in vitro susceptibility testing of the bacterial isolate.
Procaine penicillin G (86 cases due to ß-lactamase negative strains) or amoxycillin-
clavulanic acid (24 cases due to ß-lactamase positive strains) was administered par-
enterally and intramammarily for 5 days. Efﬁcacy of treatments was assessed 2 and 4
weeks later by physical examination, bacteriological culture, determination of CMT, so-
matic cell count and NAGase activity in milk. Quarters with growth of S. aureus in at
least one post-treatment sample were classiﬁed as non-cured. As controls we used 41
clinical mastitis cases caused by penicillin-susceptible S. aureus isolates treated with
procaine penicillin G parenterally for 5 days and 15 cases due to penicillin-resistant iso-
lates treated with spiramycin parenterally for 5 days from the same practice area. Bac-
teriological cure rate after the combination treatment was 75.6% for quarters infected
with penicillin-susceptible S. aureus isolates, and 29.2% for quarters infected with peni-
cillin-resistant isolates. Cure rate for quarters treated only parenterally with procaine
penicillin G was 56.1% and that for quarters treated with spiramycin 33.3%. The dif-
ference in cure rates between mastitis due to penicillin-susceptible and penicillin-
resistant S. aureus was highly signiﬁcant. Combined treatment was superior over sys-
temic treatment only in the ß-lactamase negative group.
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Introduction
In recent years, the proportion of Staphylococ-
cus aureus as a mastitis causing agent has de-
creased in many countries, including Finland
(Myllys et al. 1998). However, Staphylococcus
aureus still remains the most harmful udder
pathogen, since the disease responds poorly to
antimicrobial treatment and often remains
chronic. Quarters affected with chronic S. au-
reus mastitis may shed large amounts of bacte-
ria, increase the risk of other cows in the herd
becoming infected, and raise bulk milk somatic
cell count. In Finland and other Nordic coun-
tries, targeted treatment of bovine mastitis is
strongly recommended (Anonymous 1996,Anonymous 1998). Milk samples for bacterio-
logical examination should be taken from the
affected quarter and the antimicrobial treatment
should be based on the bacteriological diagno-
sis. The in vitro susceptibility of the bacterial
isolates should be determined as appropriate;
ß-lactamase test is recommended for S. aureus
isolates, as a large proportion of them are resis-
tant to penicillin (Aarestrup & Jensen 1998,
Myllys et al. 1998). Systemic or a combination
of systemic and intramammary treatment has
been suggested to be preferable in clinical S.
aureus mastitis, due to better penetration of the
drug into the inﬂamed mammary tissue (Ziv
1980,  Franklin et al. 1986,  Sandholm et al.
1990, Prescott et al. 2000). Studies on the efﬁ-
cacy of systemic treatment of staphylococcal
mastitis are not abundant (Funke 1982, Jarp et
al. 1989, Pyörälä & Pyörälä 1998), and even
less has been published on the effect of combi-
nation treatment (Owens et al. 1988, Perner et
al. 2002). In many mastitis studies, no attention
has been paid to the in vitro susceptibility of the
causing agent.
The aim of this study was to determine the ef-
fect of a 5-day targeted combination treatment
on clinical S. aureus mastitis caused by ß-lacta-
mase negative or positive isolates.
Materials and methods
The materials were collected in the practice
area of the Ambulatory Clinic of the Faculty of
Veterinary Medicine between years 1989 and
1997 and consisted of 166 quarter cases of clin-
ical mastitis caused by S. aureus in 118 cows
from 72 commercial dairy farms. The majority
of the cows was of the Finnish Ayrshire breed.
The median age of the cows was 4 years (third
lactation), and 21% of the cows were in their
ﬁrst lactation. All cases of clinical mastitis
caused by S. aureus and meeting the inclusion
criteria were taken to the study materials. The
inclusion criteria were as follows: antimicrobial
treatment according to the study design and no
concomitant systemic disease, teat lesions or
chronic mastitis, i.e. mastitis that had persisted
during the dry period or had been treated at
least 2 times during the same lactation or had
caused elevated somatic cell count for a long
period, i.e. months. The ﬁrst part of the study
material originates from a larger ﬁeld trial
where the effects of different cow factors and
duration of treatment were investigated (Pyö-
rälä & Pyörälä 1998). From that material, 56
cases of clinical mastitis caused by S. aureus
and treated for 5 days were included in the pre-
sent study. The second part of the material was
collected after the ﬁrst part by the same veteri-
narians on the same practice area. In brief, the
farmers contacted the veterinarians of the Am-
bulatory Clinic when they detected a case of
mastitis in the herd. The veterinarian visited the
farm, examined the cow and estimated milk so-
matic cell count (SCC) using the California
Mastitis Test (CMT). The history of the cow
(identity, age, stage of lactation etc.) was
recorded. Local and systemic clinical signs, in-
cluding rectal temperature, and milk appear-
ance were observed and recorded on a form.
Using the notes on the forms the signs were
later scored from 1 to 3, where 1 = clots and
ﬂakes seen in the milk but no other signs, 2 =
body temperature 39.0-40.5°C and/or slight
anorexia/depression, swelling and/or tender-
ness in the affected quarter and moderate
changes in milk appearance, and 3 = body tem-
perature >40.5°C and/or severe anorexia and
depression and/or recumbent, severe swelling,
ﬁrmness and soreness in the quarter and severe
changes in the milk appearance. For statistical
analyses, scores 2 and 3 were grouped together:
1 = mild signs and 2 & 3 = moderate/severe
signs. The veterinarian took an aseptic milk
sample from the affected quarter(s) for bacteri-
ological examination and N-acetyl-ß-D-glu-
cosaminidase (NAGase) activity determination.
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treatment immediately with penicillin G, if
there was no reason, based on history of the
herd, to suspect that mastitis was caused by
ß-lactamase positive S. aureus. In milder cases
(sign score 1), the treatment was started after
having obtained the bacterial diagnosis and the
result of the ß-lactamase test, which usually
took 2 additional days. 
Milk samples were cultured for bacteriological
diagnosis in the laboratory of the Ambulatory
Clinic by use of routine methods (Honkanen-
Buzalski & Seuna 1995). The S. aureus isolates
were divided into ß-lactamase positive and
negative by use of a ß-lactamase test (Myllys
1995). A total of 127 isolates proved to be in
vitro ß-lactamase negative, and 39 positive.
ß-lactamase positive isolates were tested to be
in vitro susceptible to the antibiotic used in the
trial by an agar diffusion test (Myllys 1995).
NAGase activity in the milk of the affected
quarter taken on the day of diagnosis and at the
follow-up visits was determined (Pyörälä &
Pyörälä 1997) in the laboratory of the Ambula-
tory Clinic. 
Cows with mastitis caused by ß-lactamase neg-
ative S. aureus were treated with procaine peni-
cillin G (Ethacilin, Intervet International, The
Netherlands; or Penovet, Boehringer Ingelheim
Agrovet A/S, Denmark) parenterally at a dose
of 20 mg/kg once a day for 5 days combined
with intramammaries containing 500 mg peni-
cillin and 300 mg neomycin once a day for 4
days (Vonapen, Intervet International, The
Netherlands) (86 cases), or parenterally only at
a dose of 20 mg/kg once a day for 5 days (41
cases). Cases caused by ß-lactamase positive S.
aureus were treated with amoxycillin-clavu-
lanic acid (Synulox, Pﬁzer Animal Health, UK)
parenterally at a dose of 7.0 mg amoxycillin
and 1.75 mg clavulanic acid per kg once a day
for 5 days combined with intramammaries con-
taining 200 mg amoxycillin, 50 mg clavulanic
acid and 10 mg prednisolone once a day for 4
days (Synulox Lactating Cow, Pﬁzer) (24 cases)
or parenterally only with spiramycin (Spi-
ramycin, Rhône Mérieux, France) at a dose of
10 mg/kg once a day for 5 days (15 cases). The
ﬁrst injection of spiramycin was given intra-
venously by the veterinarian, the rest of the in-
jections intramuscularly by the herd owner.
Efﬁcacy of treatment was assessed twice by
physical examination of the udder, bacteriolog-
ical culturing and determination of SCC and
NAGase activity in milk about 2 weeks (mean
14.9 days, min. 10 days, max. 23 days) and 4
weeks (mean 29.2 days, min. 26 days, max. 37
days) after the beginning of the treatment. SCC
was determined in the laboratory of the Ambu-
latory Clinic using Coulter Counter method
(Tolle et al. 1966). NAGase activity less than 40
U was classiﬁed as cured (Pyörälä & Pyörälä
1997). A quarter was classiﬁed as bacteriologi-
cally cured if growth of S. aureus was not de-
tected in either of the post-treatment milk sam-
ples. For the groups with parenteral treatment
alone, follow-up visits were made only once,
about 4 weeks (mean 29.7 days, min. 20 days,
max. 48 days) after the treatment, and SCC was
not determined. In the comparisons between the
treatment groups, only results from the post-
treatment sample at 4 weeks after treatment
were used. 
Logistic regression analyses were used to test
the effects of the following variables on the cure
rates: penicillin susceptibility, treatments, par-
ity (ﬁrst or subsequent), stage of lactation (1-14
days post partum or >14 days post partum) and
severity of mastitis on the day of diagnosis,
measured by NAGase activity, CMT score or
score of the clinical signs (mild or moderate/se-
vere). Cows from the same farm and different
quarters from the same cow were treated as if
they were independent observations because
the numbers of repeated observations of cows
and quarters were small. The effect of the peni-
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using a model where penicillin susceptibility
and parity (ﬁrst or subsequent) were included as
factors. The effects of treatments were tested
separately for the penicillin susceptible and re-
sistant groups using a model where treatment
and parity were included as factors. Variables
that were not signiﬁcantly related to the cure
rate (likelihood ratio test) were dropped from
the models. The difference between proportion
of moderate and severe signs in early (ﬁrst 14
days post partum) and later lactation was tested
using the Chi-square test.
Results
Mastitis caused by ß-lactamase negative S. au-
reus was found to have signiﬁcantly higher cure
rate than mastitis caused by ß-lactamase posi-
tive S. aureus(p<0.001). The treatment (combi-
nation versus parenteral only) affected the bac-
teriological cure rate in the ß-lactamase nega-
tive group signiﬁcantly (p = 0.009), but not in
the ß-lactamase positive group (p=0.211). The
results of the treatments for the different treat-
ment groups are shown in Table 1. The number
of post-treatment samples (1 or 2) had some ef-
fect on the results: In 4 out of 38 cases with no
cure growth of S. aureus was detected 2 weeks
after treatment but not 4 weeks after treatment.
On the other hand, in 11 cases S. aureus growth
was detected in the second but not in the ﬁrst
follow-up sample. All quarters with bacterio-
logical cure were also clinically cured. The
results for clinical cure are not given sepa-
rately.
The bacteriological cure rate was signiﬁcantly
higher in the cows in their ﬁrst lactation com-
pared with subsequent lactations (p = 0.027) in
the ß-lactamase negative group, but not in the
ß-lactamase positive group (p=0.886). In the
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Table 1. Cure rates for different treatment groups with clinical mastitis caused by in vitro penicillin-suscepti-
ble or penicillin-resistant S. aureus. Cows were treated with parenteral administration alone or with concomitant
parenteral and intramammary administration; duration of all treatments was 5 days. The efﬁcacy of the treatment
was assessed 2 and 4 weeks post-treatment for those treated with combined treatment and 4 weeks post-treat-
ment for those treated parenterally only. 
Cure rates
Bacteriological Milk NAGase4 Total5
Quarters 1 control2 2 controls3
Treatment n n % n % n % n %
Pen. G susceptible, total 127 91 71.7a 80 63.0e 71 55.9i
Systemic 41 23 56.1c 23 56.1 20 48.8
Systemic+IMM1 86 68 79.1d 65 75.6 57 66.3 51 59.3
Pen. G resistant, total 39 13 33.3b 13 33.3f 7 17.9j
Spiramycin systemic 15 5 33.3 8 53.3g 5 33.3
Amox.-clavul.systemic+IMM1 24 8 33.3 7 29.2 5 20.8h 2 8.3
Total 166 104 62.7 93 56.0 78 47.0
1 IMM = intramammary administration
2 S. aureus not detected 4 weeks post-treatment
3 S. aureus not detected 2 and 4 weeks post-treatment
4 NAGase <40 U 4 weeks post-treatment
5 Total cure = clinical plus bacteriological cure and milk NAGase value <40 U 4 weeks post-treatment
Signiﬁcance of difference: a-b: p<0.001, c-d: p=0.028, e-f: p=0.023, g-h: p=0.028, i-j: p<0.001.ﬁrst lactation cows with mastitis caused by
ß-lactamase negative bacteria, 22 out of 24
quarters (91.7%) and in older cows, 69 out of
103 quarters (67.0%) were bacteriologically
cured. In the group with mastitis due to peni-
cillin-resistant strains, 3 out of 7 cases (42.9%)
of cows on their ﬁrst lactation and 15 out of 32
cases (46.9%) of cows in subsequent lactations
were cured. The stage of lactation had no effect
on the cure rates, but the proportion of moder-
ate or severe signs was signiﬁcantly (p=0.003)
higher (80.3% vs. 58.1%) during the ﬁrst 14
days post-partum than later in lactation. The
severity of the clinical symptoms on the day of
diagnosis did not affect the cure rate, although
the proportion of cows with moderate or severe
signs was slightly higher in the group that did
not recover bacteriologically (71.4% vs.
65.7%). 
When an indicator of inﬂammation (milk NA-
Gase activity) was included in the criteria of
cure, cure rates were lower. The total cure rate
(bacteriological, clinical + milk NAGase <40 U
4 weeks post-treatment) in the penicillin-sus-
ceptible group was 55.9% and in the penicillin-
resistant group 17.9% (Table 1). This difference
is highly signiﬁcant (p<0.001). The treatments
did not affect the total cure rates signiﬁcantly in
either  ß-lactamase group. Of the clinically
cured quarters, 28% were not cured bacte-
riologically, and in 38% of them milk
NAGase activity was above the threshold level.
Milk NAGase value and CMT score on the day
of diagnosis did not affect the bacteriological
cure rate. Inﬂammatory reactions in the udder,
determined with milk NAGase activity and
SCC score, decreased clearly during the follow-
up period in the bacteriologically cured quar-
ters but remained at higher levels in quarters
with no bacteriological cure. Fig. 1 shows milk
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Figure 1. Mean milk SCC and NAGase activity in the quarters with bacteriological cure vs no cure on the day
of diagnosis and at 2 and 4 weeks post-treatment. On the day of diagnosis, milk SCC was estimated using the
California Mastitis Test.
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Discussion
The most signiﬁcant factor affecting the cure
rates for clinical S. aureus mastitis was the abil-
ity of the isolate to produce ß-lactamase. This
has also been shown by other authors (Sol et al.
2000), and could indicate either that penicillin-
resistant strains are more virulent than peni-
cillin-susceptible strains, or that the antibiotics
used to treat mastitis caused by penicillin-resis-
tant strains are less efﬁcient, due to pharma-
cokinetic or pharmacodynamic factors. The lat-
ter explanation was suggested by Ziv & Storper
(1985), who studied subclinical staphylococcal
mastitis and also found inferior cure rates for
mastitis due to penicillin-resistant isolates com-
pared with cases caused by penicillin-suscepti-
ble isolates. In the study of Sol et al. (2000),
clinical S. aureus mastitis caused by ß-lacta-
mase positive or negative isolates was treated
intramammarily with 5 different antimicrobial
treatments. The isolates were found to be in
vitro susceptible to the drug used. No differ-
ence in the bacteriological cure rates between
the different antimicrobial treatments in either
group was found, but the difference in bacterio-
logical cure rates between mastitis due to ß-lac-
tamase positive and negative strains was signif-
icant.  S. aureus is known to possess many
virulence factors, like capsule and slime forma-
tion, which make them more resistant to an-
timicrobial treatment (Sandholm et al. 1990,
Baselga et al. 1994). The possible relationship
between production of ß-lactamase and other
virulence factors of S. aureushas, to our knowl-
edge, not been investigated. 
Systemic treatment was introduced to mastitis
therapy decades ago on the basis of experimen-
tal studies (Ullberg et al. 1958, Ziv 1980). The
superiority of systemic treatment over intra-
mammary treatment has never been proven in
comparative clinical trials. However, based on
published information from separate studies,
there is some evidence that systemic treatment
may be more efﬁcient in S. aureus mastitis (Ziv
& Storper 1985,  Aungier & Austin 1987,
Owens et al. 1988, Pyörälä & Pyörälä 1998,
Deluyker et al. 1999, Knight et al. 2000). Mas-
titis caused by S. aureus is often intracellular
and penetrates deep into the tissue. Drugs that
are administered systemically penetrate better
into infection foci (Ziv 1980). As regards the
pharmacokinetics of the antimicrobials used
here, with parenterally administered penicillin
G at the dosing we used, therapeutic concentra-
tions in the udder for susceptible S. aureus
strains can be maintained (Franklin et al. 1986).
Spiramycin penetrates well into the udder and
milk when administered parenterally at the
dosage used in this study (Franklin et al. 1986),
but milk strongly reduces its antibacterial activ-
ity (Louhi et al. 1992). Information about the
pharmacokinetics of systemic amoxycillin-
clavulanic acid suspension in dairy cows is al-
most totally lacking, but in view of the low dose
used here as recommended by the manufacturer
and according to the literature which is avail-
able (Prescott et al. 2000), therapeutic concen-
trations could hardly be achieved in the udder.
The treatment effect found here was thus
mainly based on the intramammary component. 
Intramammary treatment given to supplement
systemic administration of antimicrobials in-
creases drug concentration in the milk com-
partment, and higher concentrations throughout
the mammary gland will follow (Ullberg et al.
1958, Ziv 1980). In theory, combination treat-
ment thus should improve cure rates for deep
infections such as S. aureus mastitis (Sandholm
et al. 1990). On the other hand, ß-lactam an-
timicrobials are time-dependent drugs, and
very high concentrations at the infection site do
not increase efﬁcacy (Craig 1993). Our results
show that in cases of mastitis caused by ß-lac-
tamase negative S. aureus strains, combined
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than systemic treatment alone. Previous studies
on the effect of combination treatments are very
scarce. In one experimental study with limited
material, Owens et al. (1988) found higher cure
rates in S. aureus mastitis as compared with in-
tramammary treatment only. No information
about ß-lactamase production of the isolate was
available in that study. In some extensive ﬁeld
trials carried out in Scandinavia, systemic or
short-term combined treatment in mastitis due
to penicillin G susceptible agents has been stud-
ied (Funke 1982, Jarp et al. 1989, Waage 1997,
Pyörälä & Pyörälä 1998). As regards mastitis
derived from penicillin-susceptible S. aureus
strains, Jarp et al. (1989) found in Norway that
a 59.5% bacteriological cure rate could be
achieved using 5-day systemic treatment with
procaine penicillin G, which is in agreement
with our results. Waage (1997) studied 5-day
intramammary treatment with penicillin G that
was supplemented parenterally for 1 or 3 days,
but did not ﬁnd any statistical differences be-
tween the 2 regimens. The average bacteriolog-
ical cure rate in that study was 52%, which is
very close to our results with systemic treat-
ment. The reason for the ﬁnding that no advan-
tage was achieved with the combination treat-
ment over the 3-day period remains unclear.
Recently, the therapeutical effects of parenteral,
intramammary and combination treatments
with amoxycillin-clavulanic acid have been
compared (Perner et al. 2002). The study mate-
rial consisted of 376 mastitis quarter cases, 159
of them caused by S. aureus and 32 by coagu-
lase-negative staphylococci. The ability of
ß-lactamase production of the staphylococci
was not tested. Combination treatment was
found to be superior over parenteral and intra-
mammary treatment only. For all causing
agents and mastitis types (acute, subclinical
and chronic), the bacteriological cure rate was
75.3%, whereas the clinical cure, which in-
cluded CMT-test, was only 40.0%.   
Different criteria used to assess cure make com-
parison of different treatment trials difﬁcult
(Pyörälä1988). In this study, strict criteria were
used to calculate total cure rates, which were
clearly lower than the bacteriological cure rates.
Inclusion of a marker indicating the inﬂamma-
tory status of the quarter could be useful, at
least if only one follow-up milk sample is taken
for bacteriological examination. The follow-up
sample should not be taken earlier than 4 weeks
after the beginning of the treatment, because
growth of S. aureus may be suppressed. Our re-
sults agree with other authors' ﬁndings (Neave
1975) in this respect. In our study, it was clearly
shown that in quarters with bacteriological
cure, milk NAGase activity decreased to the
threshold level by 4 weeks post-treatment (Fig.
1). 
Many manufacturers of mastitis preparations
have focused on broad spectrum antibiotics that
could be used to treat all mastitis cases, regard-
less of the causing agent or the antimicrobial
susceptibility of the pathogen (Prescott et al.
2000). At the same time an effort is being made
to limit the use of broad-spectrum antibiotics,
since their extensive use might promote antibi-
otic resistance (Anonymous 1996, Anonymous
1998). The cure rates for mastitis caused by S.
aureus using broad-spectrum antibiotics have
in many studies been inferior to our cure rates
with penicillin G (Wilson et al. 1996, Owens et
al. 1999). Penicillin G can be recommended as
the drug of choice in mastitis due to penicillin-
susceptible S. aureus. At the time of this study,
intramammaries containing penicillin G alone
were not available. The therapeutic effect of
intramammaries containing penicillin G and
an aminoglycoside on S. aureus is, however,
mainly based on the penicillin G component,
and the therapeutic effect of aminoglycoside in
the combination is negligible (Ødegaard & Svi-
land 2001, Taponen et al. 2003). It seems evi-
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crobials currently available for mastitis during
lactation are not effective against mastitis
caused by penicillin-resistant S. aureus. As re-
gards S. aureus mastitis in general, good milk-
ing hygiene, culling of infected cows and dry-
ing-off of the chronically infected quarters are
more effective means to control spreading of in-
fection and to decrease the incidence of masti-
tis in the herd (Saperstein et al. 1988). Testing
for  ß-lactamase production of staphylococci
isolated from mastitis should be included in
practice as a routine method since it brings
valuable information concerning prognosis and
prevention strategies of mastitis in the herd.
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Sammendrag
Effekten av en riktad 5 dagars kombinerad parenteral
och intramammar behandling av klinisk mastit föror-
sakad av pencillinkänslig och penicillinresistent
Staphylocuccus aureus.
En kombination av parenteral och intramammär be-
handling av mastit jämnfördes med endast parenteral
behandling. Studien omfattade kor med klinisk mas-
tit (166 juverdelar med mastit) orsakad av Staphylo-
coccus aureus. Korna behandlades av veterinärer
från veterinärmedicinska fakultetens ambulatoriska
klinik under normala gårdsbesök. Behandlingen ba-
serade sig på in vitro känslighetstestning av bakteri-
eisolaten. Procaine penicillin G (86 fall orsakade av
ß-laktamas-negativa isolat) eller amoxycillin-clavu-
lan syra (24 fall orsakade av ß-laktamas-positiva iso-
lat) administrerades parenteralt i 5 dagar och intra-
mammärt i 4 dagar. Behandlingens effektivitet kon-
trollerades 2 och 4 veckor senare genom klinisk un-
dersökning, bakteriologisk odling och undersökning
av somatiskt celltal och NAGase-aktivitet i mjölken.
Juverdelar med S. aureus -växt i det ena eller båda
proverna tagna efter behandlingen klassiﬁcerades
som icke-tillfrisknade. Som kontroller användes 41
fall av klinisk mastit orsakade av penicillinkänsliga
S. aureus -isolat, som behandlats parenteralt med
procaine penicillin G i 5 dagar och 15 fall orsakade
av penicillinresistenta isolat, som behandlats paren-
teralt med spiramycin i 5 dagar, båda från samma
praktikområde som testgruppen. Bakteriell avläk-
ning efter kombinationsbehandlingen var 75.6% för
juverdelar infekterade med penicillinkänsliga S. au-
reus-isolat och 29.2% för juverdelar infekterade med
penicillinresistenta isolat. Tillfriskningsgraden för
fall behandlade parenteralt med endast procaine pe-
nicillin G var 56.1% och för fall behandlade med spi-
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mellan mastit orsakad av penicillinkänslig och peni-
cillinresistent  S. aureus var starkt signiﬁkant. Be-
handlingen inverkade signiﬁkant på tillfriskningsgra-
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